Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 1.43% | 73.64 | 0.9% | $618.50m | |
| CELG | Celgene Corporation | 1.91% | 129.86 | 1.1% | $445.98m | |
| AMGN | Amgen Inc. | 1.30% | 170.34 | 1.1% | $413.39m | |
| BIIB | Biogen Inc. | 1.26% | 286.71 | 1.2% | $361.14m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.26% | 480.35 | 2.7% | $325.98m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.34% | 153.99 | 1.9% | $237.44m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 3.17% | 137.65 | 1.9% | $221.39m | |
| ILMN | Illumina, Inc. | 1.48% | 193.51 | 3.5% | $217.92m | |
| INCY | Incyte Corporation | 0.98% | 122.08 | 2.6% | $133.06m | |
| CLVS | Clovis Oncology, Inc. | -0.87% | 70.58 | 18.0% | $128.07m | |
| KITE | Kite Pharma, Inc. | 1.63% | 136.09 | 16.1% | $126.91m | |
| TSRO | TESARO, Inc. | -0.43% | 118.35 | 14.7% | $123.56m | |
| A | Agilent Technologies, Inc. | 1.43% | 62.62 | 1.5% | $122.20m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.88% | 81.31 | 4.4% | $106.89m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.76% | 36.00 | 19.8% | $98.17m |
Company Profile
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.